Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Urothelial Cancer Drugs Market Outlook to 2023: Merck, Roche, Bristol-Myers Squibb, AstraZeneca, and Pfizer are Dominating - ResearchAndMarkets.com

Research and Markets
Posted on: 31 Oct 18

The "Urothelial Cancer Drugs Market Size, Share & Trends Analysis Report By Treatment Class (Chemotherapy, Immunotherapy), By Major Markets, Competitive Landscape, And Segment Forecasts, 2018 - 2023" report has been added to ResearchAndMarkets.com's offering.

The global urothelial cancer drugs market size is expected to reach USD 3.6 billion by 2023, exhibiting a 22.9% CAGR during the forecast period.

Availability of novel drugs, presence of a strong pipeline, rising disease incidence, unhealthy lifestyle, and increasing awareness are driving this market.

Bladder transitional cell carcinoma (TCC) is the most common histology, accounting for nearly 90% of all urinary cancer cases.

Key Findings

  • The U.S. dominated the urothelial cancer market, with more than 60% of the market in 2017. Several factors such as presence of a large target population, increased adoption of novel therapeutics, and multiple product launches will drive the market in this region.
  • The therapeutic landscape is expected to witness a paradigm shift toward combination therapies and novel immuno-oncology products. Combination regimens, particularly checkpoint inhibitors, are likely to be introduced in the first-line setting. Immune checkpoint blockade therapy is expected to replace the current standard of care in bladder cancer in the foreseeable future.
  • Therapeutic development in second-line setting for chemotherapy-intolerant patients is expected to have a major impact in the urothelial cancer space.
  • Urothelial cancer presents a strong opportunity for introducing first-in-class treatments due to high unmet needs. Opportunities remain in the non-muscle invasive bladder cancer (NMIBC) setting where there exists an unmet need for treatment options for patients who are BCG-intolerant or ineligible.

Key Companies Profiled

  • Merck
  • Roche
  • Bristol-Myers Squibb
  • AstraZeneca
  • Pfizer

Topics Covered

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

Chapter 4 Global Urothelial Cancer Drugs Market Overview

Chapter 5 Urothelial Cancer Drugs Market: Pipeline Intelligence

Chapter 6 Company Profiles

Chapter 7 Market Outlook

For more information about this report visit https://www.researchandmarkets.com/research/rp537m/global_urothelial?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181031005327/en/

Business Wire
www.businesswire.com

Last updated on: 31/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.